circulating tumor DNA
Natera Submits Signatera Bladder Cancer PMA Module to FDA
The module relates to manufacturing and quality control systems for Signatera as a CDx in muscle-invasive bladder cancer.
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
Invitae Publishes First Validation Data on MRD Assays, Laying Path to Future Clinical Expansion
Premium
The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
I-SPY 2 Trial to Evaluate Natera's Signatera for Post-Neoadjuvant Breast Cancer Monitoring
Researchers will evaluate the MRD test's ability to monitor neoadjuvant treatment response in 600 breast cancer patients in real time.